Menu
Menu
Aurobindo Pharma's Telangana facility recently underwent an FDA inspection, resulting in two procedural observations. While these observations are not related to product quality, the company plans to address them promptly. In the meantime, Aurobindo continues to show strong financial performance, driven by sales growth in key markets like Europe and the U.S.
Lupin Pharmaceuticals faces a significant moment as its Pune biotech facility receives five observations from the FDA during a recent pre-approval inspection. While this poses regulatory challenges, the company continues to showcase robust financial growth, with a 76% increase in net profit. In this post, we delve into the implications of the FDA's findings, Lupin's strategies for addressing these issues, and what it means for investors and the future of its biotech products
Torrent Pharmaceuticals has been issued a USFDA Form 483 with five observations following an inspection of their Gujarat manufacturing facility, highlighting critical compliance areas that need immediate attention. After a thorough inspection, the USFDA issued a Form 483 to Torrent Pharmaceuticals with five key observations, emphasizing the need for stringent quality control and documentation practices at their Gujarat plant. The USFDA's recent inspection of Torrent Pharmaceuticals' Gujarat unit resulted in a Form 483 with five observations, shedding light on compliance issues that could impact future product approvals. Torrent Pharmaceuticals faces a significant regulatory challenge as the USFDA issues a Form 483 with five observations after inspecting their Gujarat facility, focusing on critical areas of improvement. The USFDA's Form 483 issued to Torrent Pharmaceuticals' Gujarat plant includes five critical observations, raising concerns about compliance and the potential effects on the company's product approvals.